Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
Drugs by status
Approved for this indication (2)
Phase 4 trials (16)
Phase 3 trials (25)
- abetimus
- secukinumab
- anifrolumab
- beta glucosylceramide
- cenerimod
- diphenhydramine
- prednisone
- dexchlorpheniramine maleate
- betamethasone
- obinutuzumab
- aldesleukin
- baricitinib
- mizoribine
- ocrelizumab
- atacicept
- acetaminophen
- sirolimus
- cyclosporine
- leflunomide
- abatacept
- tripterygium wilfordii
- vay736
- umbilical cord mesenchymal stem cells
- infliximab
- phosphate
Phase 2 trials (46)
- cfz533
- etanercept
- guselkumab
- bone marrow derived mesenchymal stem cells
- ganciclovir
- laquinimod
- nipocalimab
- milatuzumab
- gusperimus
- Narsoplimab
- bi 655064
- tamibarotene
- shr-1314
- sirukumab
- cd19 car-t cells
- autologous mesenchymal stem cells
- fludarabine
- daratumumab
- biib-023
- ruplizumab
- turmeric
- ravulizumab-cwvz
- zanubrutinib
- Zetomipzomib
- Iptacopan
- iguratimod
- vib4920
- tafasitamab
- efgartigimod
- cc-97540
- +16 more
Phase 1 trials (36)
- ixazomib
- allogeneic hematopoietic stem cells
- regn1979
- autologous regulatory t cells
- amniotic stem cells
- bcma-pd1-cart cell
- itolizumab
- allogeneic gamma-delta t cells
- ab-101
- regn5459
- ct-rd06
- mor202
- cd19 car-nk cells
- anx009
- cb-010
- kite-363
- tak-007
- cnty-101
- cug252
- pit565
- ctx112
- stk-009
- syncar-001
- cln-978
- dr-0201
- fkc288
- sc291
- prg-1801
- ata3219
- prg-2311
- +6 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (26)
- Astellas
- Mallinckrodt
- Huazhong University of Science and Technology
- Central South University
- Case Western Reserve University
- Chulalongkorn University
- Cornell University
- Ohio State University
- The Rogosin Institute
- Chinese University of Hong Kong
- Columbia University
- Fujian Medical University
- Nanchang University
- University of Cincinnati
- Bangladesh Medical University
- Jiao Tong University
- Al Azhar University
- The University of Hong Kong
- Sun Yat-Sen University
- Jawaharlal Institute of Postgraduate Medical Education and Research
- Tuen Mun Hospital, Hong Kong
- Ningxia Medical University
- China Medical University
- The Cleveland Clinic
- The First People's Hospital of Yunan Province
- Berlin Pharmaceutical Industry Co., LTD.
Organization Involved with Phase 3 Indications (51)
- Human Genome Sciences
- Bristol-Myers Squibb
- Roche
- Merck Serono
- Genentech
- Novartis
- Aurinia Pharmaceuticals Inc.
- GlaxoSmithKline
- La Jolla Pharmaceutical Company
- ZymoGenetics
- Medical University of Graz
- University of London
- Guangxi Medical University
- Guangzhou Medical University
- Hospital General Universitario Gregorio Marañon
- Hospital Infanta Sofia
- Hospital Universitario Fundación Alcorcón
- Radboud University
- Sichuan University
- Universidad Complutense de Madrid
- University of Groningen
- Peking University
- University of Cambridge
- Université catholique de Louvain
- Tsinghua University
- University of Vienna
- Leiden University
- Southern Medical University
- Karolinska Institute
- Hospital Universitario Infanta Leonor
- +21 more
Organization Involved with Phase 2 Indications (40)
- Immunomedics
- AstraZeneca
- Biogen
- Alexion
- BeOne Medicines
- Nippon Kayaku Co.,Ltd.
- Omeros Corporation
- Parexel
- Red de Terapia Celular
- Teva
- Apellis Pharmaceuticals, Inc.
- Boehringer Ingelheim
- Genovate Biotechnology Co., Ltd.,
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Masaryk University
- Nanjing University
- Organ Transplant Institute, China
- Palacky University
- Seoul National University
- University of Heidelberg
- Chitwan Medical College
- University of California, San Francisco
- Feinstein Institute for Medical Research
- Department of Defense
- Taipei Veteran General hospital
- Universidad de los Andes
- Hospital Rio Hortega
- Janssen Pharmaceutica NV
- University of Valladolid
- +10 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (21)
- Changhai Hospital
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Mahidol University
- Nanjing Medical University
- Northwell Health
- Siriraj Hospital
- Capital Medical University
- Fudan University
- Prince of Songkla University
- Wenzhou Medical University
- Dalian Medical University
- Soochow University
- Shandong University
- Anhui College of Traditional Chinese Medicine
- Maharaj Nakorn Chiang Mai Hospital
- Government of Mexico
- Rajavithi Hospital, Bangkok
- KhonKaen University
- Bengbu Medical College
- AnHui ShengLi Hospital
- Jinlin University